Therapeutic Drug Monitoring of Ivacaftor, Lumacaftor, Tezacaftor, and Elexacaftor in Cystic Fibrosis: Where Are We Now?

Therapeutic Drug Monitoring of Ivacaftor, Lumacaftor, Tezacaftor, and Elexacaftor in Cystic Fibrosis: Where Are We Now?

Drugs modulating the cystic fibrosis transmembrane conductance regulator (CFTR) protein, namely ivacaftor, lumacaftor, tezacaftor, and elexacaftor, are currently revolutionizing the management of patients with cystic fibrosis (CF), particularly those with at least one <i>F508del</i> vari...

Full description

Bibliographic Details
Main Authors: Eva Choong, Alain Sauty, Angela Koutsokera, Sylvain Blanchon, Pascal André, Laurent Decosterd
Format: Article
Language:English
Published: MDPI AG 2022-08-01
Series:Pharmaceutics
Subjects:
TDM
therapeutic drug monitoring
plasma level
PK/PD
dose–effect relationship
cystic fibrosis
Online Access:https://www.mdpi.com/1999-4923/14/8/1674

Similar Items

Similar Items